BIOMARKER:

BCR-ABL1 E255K

Entrez ID:

Related biomarkers:

‹

›

BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
BCR-ABL1 E255K BCR-ABL1 E255K	Acute Lymphocytic Leukemia ALL	BCR-ABL1 E255K BCR-ABL1 E255K	Acute Lymphocytic Leukemia ALL	nilotinib Resistant: A2 - Guideline	nilotinib Resistant: A2 - Guideline
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	dasatinib Sensitive: B - Late Trials	dasatinib Sensitive: B - Late Trials
BCR-ABL1 E255K BCR-ABL1 E255K	Acute Lymphocytic Leukemia ALL	BCR-ABL1 E255K BCR-ABL1 E255K	Acute Lymphocytic Leukemia ALL	dasatinib + blinatumomab Sensitive: C3 – Early Trials	dasatinib + blinatumomab Sensitive: C3 – Early Trials
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	bosutinib Resistant: C3 – Early Trials	bosutinib Resistant: C3 – Early Trials
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	imatinib Resistant: C3 – Early Trials	imatinib Resistant: C3 – Early Trials
BCR-ABL1 E255K BCR-ABL1 E255K	Acute Lymphocytic Leukemia ALL	BCR-ABL1 E255K BCR-ABL1 E255K	Acute Lymphocytic Leukemia ALL	ponatinib Resistant: C3 – Early Trials	ponatinib Resistant: C3 – Early Trials
BCR-ABL1 E255K BCR-ABL1 E255K	B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia	BCR-ABL1 E255K BCR-ABL1 E255K	B Acute Lymphoblastic Leukemia B Acute Lymphoblastic Leukemia	S81694 Sensitive: D – Preclinical	S81694 Sensitive: D – Preclinical
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	CUDC-907 Sensitive: D – Preclinical	CUDC-907 Sensitive: D – Preclinical
BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	BCR-ABL1 E255K BCR-ABL1 E255K	Chronic Myeloid Leukemia CML	dasatinib + imatinib Resistant: D – Preclinical	dasatinib + imatinib Resistant: D – Preclinical